RICARDO
RUIZ VILLAVERDE
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (12)
2024
-
Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
2023
-
A Series of 69 COVID-related Dermatoses With Biopsy, Immunohistochemistry With Anti-spike 3, in situ Hybridization and PCR: A Critical Reappraisal of Viral Involvement in COVID-19 Skin Lesions
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 747-754
-
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliograficas
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study
JDDG - Journal of the German Society of Dermatology, Vol. 21, Núm. 7, pp. 741-748
-
[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501
2022
-
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*
British Journal of Dermatology, Vol. 186, Núm. 1, pp. 142-152
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
2021
-
A new classification of the severity of psoriasis: What’s moderate psoriasis?
Life, Vol. 11, Núm. 7
2020
-
Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study
Dermatologic Therapy, Vol. 33, Núm. 6
-
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829